HRSA responds to AHA outreach regarding Johnson & Johnson’s unilateral imposition of 340B rebate model 

Aug 23, 2024 - 02:34 PM
340B pic

Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products, Stelara and Xarelto. Starting Oct. 15, J&J will require all disproportionate share hospitals participating in the 340B Drug Pricing Program to purchase these drugs at full price and submit data to J&J. Upon verification of the drug’s 340B status, DSHs would receive a rebate for the discounted 340B price.

Last week, the AHA contacted the Health Resources and Services Administration for more information as soon as it was made aware that J&J was considering these actions. HRSA notified the AHA today that it has informed J&J that its rebate model is inconsistent with the 340B statute and that this model has not been approved by the Secretary of the Department of Health and Human Services. HRSA further informed the AHA that it will take appropriate action as warranted.
 

Related News Articles

Headline
AHA files amicus brief in Minnesota defending its 340B contract pharmacy law
The AHA, 340B Health, the Minnesota Hospital Association and American Society of Health-system Pharmacists Oct. 4 filed an amicus brief in the U.S. District…
Headline
Louisiana district court upholds state 340B contract pharmacy law
A Louisiana district court Sept. 30 upheld a state law prohibiting drug companies from denying Louisiana hospitals 340B discounts for drugs dispensed at…
Headline
As urged by the AHA and others, J&J tells HRSA it is abandoning proposed 340B rebate plan 
Johnson & Johnson Sept. 30 notified the Health Resources and Services Administration that it is ceasing implementation of its proposed 340B rebate model.…
Headline
HRSA issues final warning to J&J to cease implementation of its 340B proposed rebate program
The Health Resources and Services Administration Sept. 27 sent a final warning letter to Johnson & Johnson urging the company to inform the agency by…
Headline
AHA op-ed in Medical Economics sets the record straight on 340B program growth and the role of drug companies
“As pharmaceutical companies throw stone after stone at the 340B program, they should beware of their own glass house. Their complaints ring hollow when it is…
Headline
HRSA to J&J: Cease implementation of proposed 340B rebate model
The Health Resources and Services Administration Sept. 17 told Johnson & Johnson that the company’s publicly announced plans to implement a 340B rebate…